{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T12:33:03Z","timestamp":1794227583980,"version":"4.9.0"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001674","name":"Leducq Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001674","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministry of Health","doi-asserted-by":"publisher","award":["GR-2021-12371950"],"award-info":[{"award-number":["GR-2021-12371950"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011713","name":"Worldwide Cancer Research","doi-asserted-by":"publisher","award":["25-0373"],"award-info":[{"award-number":["25-0373"]}],"id":[{"id":"10.13039\/100011713","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011713","name":"Worldwide Cancer Research","doi-asserted-by":"publisher","award":["19CVD02"],"award-info":[{"award-number":["19CVD02"]}],"id":[{"id":"10.13039\/100011713","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["PRIN 2022 PNRR P20229WSC9"],"award-info":[{"award-number":["PRIN 2022 PNRR P20229WSC9"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["PRIN 2022 20223YPL49"],"award-info":[{"award-number":["PRIN 2022 20223YPL49"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["PRIN PNRR 2022 P2022ZB72T"],"award-info":[{"award-number":["PRIN PNRR 2022 P2022ZB72T"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.coph.2025.102581","type":"journal-article","created":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T01:59:30Z","timestamp":1759543170000},"page":"102581","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Immune cell subtype contributions to doxorubicin cardiotoxicity\u2013defining immune targets for translational interventions"],"prefix":"10.1016","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4891-4402","authenticated-orcid":false,"given":"Jens","family":"Van fraeyenhove","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Guerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Hirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1193-5296","authenticated-orcid":false,"given":"Alessandra","family":"Ghigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2025.102581_bib1","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.coph.2025.102581_bib2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jaccao.2022.01.101","article-title":"The role of cardioprotection in cancer therapy cardiotoxicity: JACC: cardiooncology state-of-the-art review","volume":"4","author":"Omland","year":"2022","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.coph.2025.102581_bib3","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.006915","article-title":"Cardiotoxicity from human epidermal growth factor Receptor-2 (HER2) targeted therapies","volume":"6","author":"Florido","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.coph.2025.102581_bib4","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s00395-016-0576-z","article-title":"ErbB2 signaling at the crossing between heart failure and cancer","volume":"111","author":"Vermeulen","year":"2016","journal-title":"Basic Res Cardiol"},{"key":"10.1016\/j.coph.2025.102581_bib5","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/nrc2106","article-title":"Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition","volume":"7","author":"Force","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.coph.2025.102581_bib6","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3389\/fcvm.2020.00035","article-title":"Mechanisms of anthracycline-induced cardiotoxicity: is mitochondrial dysfunction the answer?","volume":"7","author":"Murabito","year":"2020","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.coph.2025.102581_bib7","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/s10741-025-10531-0","article-title":"Cancer therapy-induced cardiotoxicity: mechanisms and mitigations","volume":"5","author":"Shil","year":"2025","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.coph.2025.102581_bib8","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.jaccao.2023.08.003","article-title":"Priorities in cardio-oncology basic and translational science: GCOS 2023 symposium proceedings: JACC: cardiooncology state-of-the-art review","volume":"5","author":"Salloum","year":"2023","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.coph.2025.102581_bib9","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1146\/annurev-pharmtox-030620-104842","article-title":"Preventing and treating anthracycline cardiotoxicity: new insights","volume":"61","author":"Sawicki","year":"2021","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.coph.2025.102581_bib10","first-page":"111","article-title":"Cardiotoxicity of anthracyclines","volume":"43","author":"Balough","year":"2025","journal-title":"Cardiol Clin"},{"key":"10.1016\/j.coph.2025.102581_bib11","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41514-024-00135-7","article-title":"A review of the pathophysiological mechanisms of doxorubicin-induced cardiotoxicity and aging","volume":"10","author":"Linders","year":"2024","journal-title":"npj Aging"},{"key":"10.1016\/j.coph.2025.102581_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111708","article-title":"Doxorubicin-induced cardiotoxicity: an update on the molecular mechanism and novel therapeutic strategies for effective management","volume":"139","author":"Rawat","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.coph.2025.102581_bib13","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1007\/s00204-023-03586-1","article-title":"The role of inflammation and antioxidant defenses in the cardiotoxicity of doxorubicin in elderly CD-1 male mice","volume":"97","author":"Reis-Mendes","year":"2023","journal-title":"Arch Toxicol"},{"key":"10.1016\/j.coph.2025.102581_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/biom11111725","article-title":"Role of inflammation and redox status on doxorubicin-induced cardiotoxicity in infant and adult CD-1 Male mice","volume":"11","author":"Reis-Mendes","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.coph.2025.102581_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232314649","article-title":"The innate immune system in cardiovascular diseases and its role in doxorubicin-induced cardiotoxicity","volume":"23","author":"Bhagat","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.coph.2025.102581_bib16","series-title":"Inflammation in chemotherapy-induced cardiotoxicity","author":"Hutchins","year":"2024"},{"key":"10.1016\/j.coph.2025.102581_bib17","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s12012-020-09576-4","article-title":"Involvement of ROS\/NLRP3 inflammasome signaling pathway in Doxorubicin-induced cardiotoxicity","volume":"20","author":"Wei","year":"2020","journal-title":"Cardiovasc Toxicol"},{"key":"10.1016\/j.coph.2025.102581_bib18","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/ejhf.1138","article-title":"The innate immune system in chronic cardiomyopathy: a European Society of Cardiology (ESC) scientific statement from the Working Group on Myocardial Function of the ESC","volume":"20","author":"Frantz","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.coph.2025.102581_bib19","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1161\/CIRCULATIONAHA.117.030352","article-title":"Phosphoinositide 3-Kinase gamma inhibition protects from Anthracycline cardiotoxicity and reduces tumor growth","volume":"138","author":"Li","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.coph.2025.102581_bib20","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1161\/CIRCRESAHA.121.318005","article-title":"Immune cells and immunotherapy for cardiac injury and repair","volume":"128","author":"Rurik","year":"2021","journal-title":"Circ Res"},{"key":"10.1016\/j.coph.2025.102581_bib21","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.115.003584","article-title":"Characterization of the changes in cardiac structure and function in mice treated with anthracyclines using serial cardiac magnetic resonance imaging","volume":"9","author":"Farhad","year":"2016","journal-title":"Circ Cardiovasc Imag"},{"key":"10.1016\/j.coph.2025.102581_bib22","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1093\/cvr\/cvaa222","article-title":"Cardiac dysfunction in cancer patients: beyond direct cardiomyocyte damage of anticancer drugs: novel cardio-oncology insights from the joint 2019 meeting of the ESC Working Groups of Myocardial Function and Cellular biology of the heart","volume":"116","author":"Tocchetti","year":"2020","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.coph.2025.102581_sref23","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.030200","article-title":"Zymosan A improved doxorubicin-induced ventricular remodeling by evoking heightened cardiac inflammatory responses and healing in mice","volume":"12","author":"Xu","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.coph.2025.102581_sref24","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/s44161-024-00507-y","article-title":"Cytotoxic T cells drive doxorubicin-induced cardiac fibrosis and systolic dysfunction","volume":"3","author":"Bayer","year":"2024","journal-title":"Nat Cardiovasc Res"},{"key":"10.1016\/j.coph.2025.102581_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26094071","article-title":"Interleukin-6 in anthracycline-related cardiac dysfunction: a comparison with myeloperoxidase and TNF-Alpha","volume":"26","author":"Borowiec","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.coph.2025.102581_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.yjmcc.2024.02.005","article-title":"Neutrophils are indispensable for adverse cardiac remodeling in heart failure","volume":"189","author":"Antipenko","year":"2024","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.coph.2025.102581_bib27","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.146076","article-title":"TP53-mediated therapy-related clonal hematopoiesis contributes to doxorubicin-induced cardiomyopathy by augmenting a neutrophil-mediated cytotoxic response","volume":"6","author":"Sano","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.coph.2025.102581_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.fct.2022.113421","article-title":"Inflammatory markers S100A8\/A9 and metabolic alteration for evaluating signs of early phase toxicity of anticancer agent treatment","volume":"169","author":"Morikawa-Ichinose","year":"2022","journal-title":"Food Chem Toxicol"},{"key":"10.1016\/j.coph.2025.102581_bib29","doi-asserted-by":"crossref","DOI":"10.3390\/cells11020236","article-title":"S100A8\/A9 is a marker for the release of neutrophil extracellular traps and induces neutrophil activation","volume":"11","author":"Sprenkeler","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.coph.2025.102581_bib30","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1161\/CIRCRESAHA.122.321504","article-title":"Ponatinib drives cardiotoxicity by S100A8\/A9-NLRP3-IL-1\u03b2 mediated inflammation","volume":"132","author":"Tousif","year":"2023","journal-title":"Circ Res"},{"key":"10.1016\/j.coph.2025.102581_bib31","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25179735","article-title":"Neutrophil biomarkers can predict cardiotoxicity of anthracyclines in breast cancer","volume":"25","author":"Todorova","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.coph.2025.102581_sref32","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/s00018-024-05169-4","article-title":"Neutrophil extracellular traps mediate cardiomyocyte ferroptosis via the Hippo-Yap pathway to exacerbate doxorubicin-induced cardiotoxicity","volume":"81","author":"Zhao","year":"2024","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.coph.2025.102581_bib33","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/s43018-025-00988-1","article-title":"Cardiomyocyte-localized CCDC25 senses NET DNA to promote doxorubicin cardiotoxicity by activating autophagic flux","volume":"6","author":"Nie","year":"2025","journal-title":"Nat Cancer"},{"key":"10.1016\/j.coph.2025.102581_sref34","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s00395-023-01006-0","article-title":"Myeloperoxidase is a critical mediator of anthracycline-induced cardiomyopathy","volume":"118","author":"Nettersheim","year":"2023","journal-title":"Basic Res Cardiol"},{"key":"10.1016\/j.coph.2025.102581_bib35","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1161\/CIRCRESAHA.119.316428","article-title":"Self-maintenance of cardiac resident reparative macrophages attenuates doxorubicin-induced cardiomyopathy through the SR-A1-c-Myc axis","volume":"127","author":"Zhang","year":"2020","journal-title":"Circ Res"},{"key":"10.1016\/j.coph.2025.102581_sref36","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115469","article-title":"IL-27p28 knockout aggravates Doxorubicin-induced cardiotoxicity by regulating macrophage polarization","volume":"210","author":"Feng","year":"2023","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.coph.2025.102581_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacbts.2025.02.015","article-title":"SLAMF7 restrains pro-inflammatory macrophage activation to counteract doxorubicin-induced cardiotoxicity","author":"Liu","year":"2025","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.coph.2025.102581_bib38","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.3389\/fphar.2019.01253","article-title":"The TRPA1 channel in the cardiovascular system: promising features and challenges","volume":"10","author":"Wang","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.coph.2025.102581_bib39","article-title":"TRPA1 deficiency aggravates dilated cardiomyopathy by promoting S100A8 expression to induce M1 macrophage polarization in rats","volume":"37","author":"Wang","year":"2023","journal-title":"FASEB J"},{"key":"10.1016\/j.coph.2025.102581_bib40","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222111460","article-title":"TRPA1 expression and pathophysiology in immune cells","volume":"22","author":"Naert","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.coph.2025.102581_bib41","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMoa1911326","article-title":"Emapalumab in children with primary hemophagocytic lymphohistiocytosis","volume":"382","author":"Locatelli","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2025.102581_bib42","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41569-023-00919-6","article-title":"Immunomodulation and immunopharmacology in heart failure","volume":"21","author":"Markousis-Mavrogenis","year":"2024","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.coph.2025.102581_bib43","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1038\/s41423-021-00670-3","article-title":"An update on the regulatory mechanisms of NLRP3 inflammasome activation","volume":"18","author":"Paik","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.coph.2025.102581_bib44","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26040976","article-title":"NLRP3 inflammasome inhibitors in cardiovascular diseases","volume":"26","author":"Mezzaroma","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.coph.2025.102581_bib45","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in patients with chronic coronary disease","volume":"383","author":"Nidorf","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2025.102581_bib46","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1002\/ehf2.13845","article-title":"Colchicine prevents disease progression in viral myocarditis via modulating the NLRP3 inflammasome in the cardiosplenic axis","volume":"9","author":"Pappritz","year":"2022","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.coph.2025.102581_bib47","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1002\/ejhf.3636","volume":"6","author":"Ghigo","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.coph.2025.102581_bib48","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/s41590-021-00886-5","article-title":"NLRP3 inflammasome in cancer and metabolic diseases","volume":"22","author":"Sharma","year":"2021","journal-title":"Nat Immunol"},{"key":"10.1016\/j.coph.2025.102581_bib49","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.jaccao.2024.10.010","article-title":"Shared mechanisms in cancer and cardiovascular disease: S100A8\/9 and the NLRP3 inflammasome: JACC: cardiooncology state-of-the-art review","volume":"7","author":"Van Linthout","year":"2024","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.coph.2025.102581_bib50","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.014941","article-title":"Interleukin-1 blockade inhibits the acute inflammatory response in patients with ST-Segment\u2013Elevation myocardial infarction","volume":"9","author":"Abbate","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.coph.2025.102581_bib51","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12134458","article-title":"Empagliflozin reduces Interleukin-6 levels in patients with heart failure","volume":"12","author":"Gotzmann","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.coph.2025.102581_bib52","article-title":"Empagliflozin blunts worsening cardiac dysfunction associated with reduced NLRP3 (Nucleotide-Binding domain-like receptor protein 3) inflammasome activation in heart failure","volume":"13","author":"Byrne","year":"2020","journal-title":"Circulation: Heart Fail"},{"key":"10.1016\/j.coph.2025.102581_bib53","series-title":"Evaluation of the effectiveness of empagliflozin in the prevention of cardiotoxicity in cancer patients undergoing chemotherapy based on anthracyclines (EMPACT Study) [Internet]","year":"2025"},{"key":"10.1016\/j.coph.2025.102581_bib54","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s10741-024-10450-6","article-title":"GLP-1 receptor agonists as promising anti-inflammatory agents in heart failure with preserved ejection fraction","volume":"30","author":"Bonfioli","year":"2025","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.coph.2025.102581_bib55","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1161\/CIRCULATIONAHA.120.045888","article-title":"Glucagon-like peptide 1 receptor agonists and heart failure","volume":"142","author":"Khan","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.coph.2025.102581_bib56","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s40959-024-00241-1","article-title":"Characterization of systolic and diastolic function, alongside proteomic profiling, in doxorubicin-induced cardiovascular toxicity in mice","volume":"10","author":"Kr\u00fcger","year":"2024","journal-title":"Cardio-Oncology"},{"key":"10.1016\/j.coph.2025.102581_bib57","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1093\/cvr\/cvad136","article-title":"Doxorubicin-induced cardiovascular toxicity: a longitudinal evaluation of functional and molecular markers","volume":"119","author":"Bosman","year":"2023","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.coph.2025.102581_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaccao.2025.05.012","article-title":"Mismatch between preclinical cardio-oncology and clinical oncology research","author":"Cagnazzo","year":"2025","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.coph.2025.102581_bib59","doi-asserted-by":"crossref","first-page":"9735","DOI":"10.3390\/ijms25179735","article-title":"Neutrophil biomarkers can predict cardiotoxicity of anthracyclines in breast cancer","volume":"25","author":"Todorova","year":"2024","journal-title":"Int J Mol Sci"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489225000773?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489225000773?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T02:55:10Z","timestamp":1778813710000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489225000773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":59,"alternative-id":["S1471489225000773"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2025.102581","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune cell subtype contributions to doxorubicin cardiotoxicity\u2013defining immune targets for translational interventions","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2025.102581","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102581"}}